Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Sequist L, Fidas P, Temel J, Kolevska T, Rabin M, Boccia R, Burris H, Belt R, Kosmo M, Huberman M, Melnyk O, Guba S, Sleckman B, Klix M, Needles B, Mills G, Englund C, Caldwell D, Tesarowski D, Brown G, Edelman M, Lynch T. Phase 2 multicenter dose-ranging trial of TLK286 (Canfosfamide HCl) (T) in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Proceedings of the 2007 Annual Meeting of the American Association for Cancer Research. 2007; abstract 3521.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.